The Role of ctDNA in Breast Cancer: Prognosis and Clinical Utility
Canadian Oncology Today · 2025
DOI: 10.58931/cot.2025.2130 ↗Kurz gefasst
Fachartikel in der Zeitschrift Canadian Oncology Today, 2025. Verfasst von Mairi Lucas und 1 weiteren Autor:innen. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Breast cancer remains the most common cancer among women globally, with significant morbidity and mortality. Current treatment for breast cancer, both in the early stage and metastatic setting, is based on a tumour biopsy and immunohistochemical detection of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor 2 (HER2) expression. Though substantial research has been undertaken over the years to establish new prognostic and predictive biomarkers in breast cancer, most have not demonstrated significant clinical utility. Circulating tumour DNA (ctDNA) is increasingly used across various cancer types for precision medicine. In this article, we discuss the current roles of ctDNA in breast cancer prognosis and its clinical utility in treatment decision-making in early- and advanced-stage settings.
Zitieren
APA
Lucas, M., & Chia, S. K. L. (2025). The Role of ctDNA in Breast Cancer: Prognosis and Clinical Utility. Canadian Oncology Today. https://doi.org/10.58931/cot.2025.2130
Vancouver
Lucas M, Chia SKL. The Role of ctDNA in Breast Cancer: Prognosis and Clinical Utility. Canadian Oncology Today. 2025. doi:10.58931/cot.2025.2130
BibTeX
@article{Lucas2025,
author = {Lucas, Mairi and Chia, Stephen K. L.},
title = {The Role of ctDNA in Breast Cancer: Prognosis and Clinical Utility},
journal = {Canadian Oncology Today},
year = {2025},
doi = {10.58931/cot.2025.2130}
}
EUVIMED